Share page on LinkedIn

ICON is a global provider of outsourced development services

ICON currently has almost 38,000 employees in 147 locations in 46 countries. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

ICON services video

Financial figures

  • Full year reported revenue for 2020 was $2.797 billion, representing an 0.3% year on year decrease or 0.5% on a constant currency basis. At the end of Q4 2020 the company had a record closing backlog of $9.7 billion, an increase of 13.4% year on year (see Q4 and full year earnings release).
  • Quarter 4 reported revenue of $760.2 million representing a year on year increase of 4.8% and 8.3% increase on Quarter 3 2020.
  • Adjusted earnings per share attributable to the Group for the quarter of $1.90, compared to $1.83 in Quarter 4 2019. Full year adjusted earnings per share* attributable to the group of $6.53, compared to $6.88 in 2019.

  • Strong cash generation resulting in a record net cash position of $494 million. Days sales outstanding reduced to 41 days from 54 days at December 31, 2019.

  • Full year 2021 revenue guidance in the range of $3,200 - $3,300 million, a year over year increase of 14.4% - 18.0%. Full Year 2021 earnings per share guidance in the range of $8.10 - $8.50, a year over year increase of 24.0% - 30.2%.

  • *before non-recurring charges.

Q2 2021 financial results

How ICON partners with sponsors and pharma